TOSCA, ELENA MARIA
 Distribuzione geografica
Continente #
NA - Nord America 593
EU - Europa 420
AS - Asia 277
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 1.294
Nazione #
US - Stati Uniti d'America 591
CN - Cina 183
IE - Irlanda 183
IT - Italia 162
SG - Singapore 70
DE - Germania 22
FI - Finlandia 18
SE - Svezia 7
FR - Francia 6
MY - Malesia 6
BE - Belgio 5
IR - Iran 5
JP - Giappone 5
NL - Olanda 5
CZ - Repubblica Ceca 3
HK - Hong Kong 3
TW - Taiwan 3
CA - Canada 2
CH - Svizzera 2
CO - Colombia 2
RU - Federazione Russa 2
AT - Austria 1
AU - Australia 1
EU - Europa 1
GB - Regno Unito 1
GR - Grecia 1
IN - India 1
KR - Corea 1
LU - Lussemburgo 1
RO - Romania 1
Totale 1.294
Città #
Dublin 183
Chandler 148
Boardman 69
Singapore 51
Pavia 49
Shanghai 39
Ashburn 36
Nanjing 31
Lawrence 26
Medford 26
Princeton 26
Beijing 21
Wilmington 20
Dearborn 17
Shenyang 17
Jacksonville 16
Hebei 15
Helsinki 15
New York 15
Nanchang 14
Milan 11
Ann Arbor 8
Changsha 8
Jiaxing 8
Tianjin 8
Brescia 6
Los Angeles 6
Mira 6
Brussels 5
Girifalco 5
Heemskerk 5
Kunming 5
Rome 5
Cagliari 4
Castano Primo 4
Dallas 4
Fairfield 4
Florence 4
Hefei 4
Moncalieri 4
Munich 4
Norwalk 4
Tokyo 4
Brno 3
Hangzhou 3
Pittsburgh 3
Springfield 3
Stezzano 3
Taipei 3
Bodman-Ludwigshafen 2
Carate Brianza 2
Comun Nuovo 2
Ellicott City 2
Frankfurt am Main 2
Genoa 2
Guangzhou 2
Hong Kong 2
Imbersago 2
Kashan 2
Lecce 2
Medellín 2
Novara 2
Piscataway 2
Prineville 2
Redwood City 2
Romano di Lombardia 2
Saronno 2
Taizhou 2
Tehran 2
Toronto 2
Washington 2
Zhengzhou 2
Zurich 2
Andover 1
Aosta 1
Atlanta 1
Bareggio 1
Borås 1
Des Moines 1
Falkenstein 1
Falls Church 1
Fayetteville 1
Forest City 1
Fort Worth 1
Hyderabad 1
Jinan 1
Kish 1
Luxembourg 1
Monmouth Junction 1
Nagold 1
Naples 1
Newark 1
Ningbo 1
Orange 1
Piacenza 1
Pohang 1
Portland 1
Redmond 1
Sacramento 1
San Francisco 1
Totale 1.053
Nome #
Evaluation of software tools for Bayesian estimation on population models:an update based on current software versions 67
Methods and tools for multiscale modelling in Systems Pharmacology: a review 66
A PK/PD model for tumor-in-host growth kinetics following administration of an antiangiogenic agent given alone or in combination regimens 61
Modeling tumor growth inhibition and toxicity outcome after administration of anticancer agents in xenograft mice: A Dynamic Energy Budget (DEB) approach 59
Cancer Cachexia: A Dynamic Energy Budget ({DEB})-Based Model for Tumor-Related Anorexia and Sarcopenia 57
Dynamic energy budget based models of tumor-in-host growth inhibition and cachexia onset in preclinical settings. 55
Artificial intelligence and machine learning: just a hype or a new opportunity for pharmacometrics? 50
In vitro– in vivo correlation (Ivivc) population modeling for the in silico bioequivalence of a long‐acting release formulation of progesterone 50
Evaluation of a PK/PD DEB-based model for tumor-in-host growth kinetics under anticancer treatment 49
In vitro-in vivo correlation (IVIVC) population modeling for the in silico bioequivalence of a long-acting release formulation of Progesterone 49
Evaluation of a tumor growth inhibition (TGI) model integrating dynamic energy budget (DEB) theory 47
A Population Dynamic Energy Budget-Based Tumor Growth Inhibition Model for Etoposide Effects on Wistar Rats 45
Modeling resistance development to Bevacizumab in xenograft experiments by coupling hypoxia-mediated mechanism and a Dynamic Energy Budget (DEB) based tumor-in-host model 41
A genetic algorithm for covariate selection 35
Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity 35
Dynamic Energy Budget (DEB) based models of tumor-in-host growth inhibition and cachexia onset 34
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib 34
Development of a genetic algorithm for covariate analysis in population pharmacokinetic models 34
A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in in vivo xenograft studies 32
Application of Artificial Neural Networks to Predict the Intrinsic Solubility of Drug-Like Molecules 32
PKPD modelling of MEN1611 anti-tumor effect in xenograft models to predict efficacy threshold concentrations in HER2-positive advanced or metastatic breast cancer patient population 32
Facing the limits of the genetic algorithms for covariate selection 31
A tumor-in-host DEB-based approach for modeling cachexia and bevacizumab resistance 31
How Modelling and Simulations combined with Artificial Intelligence can improve Precision Dosing 27
Model-based analysis of patient-derived organoids for evaluating anticancer drugs 26
A tumor-in-host Dynamic Energy Budget (DEB)-based paradigm for preclinical to clinical translation: predictions of tumor-in-host growth dynamics 26
Reduced food-intake and sarcopenia in animal models of cancer anorexia-cachexia syndrome: a Dynamic Energy Budget (DEB)-based modeling approach 25
Predicting tumor volume doubling time and progression-free survival curves in cancer patients from patient-derived-xenograft (PDX) models: a translational model-based population approach 21
Integrating Reinforcement Learning and PK-PD modelling to enable precision dosing: a multi-objective optimization for the treatment of Polycithemia Vera patients with Givinostat 20
Staggered Herringbone Microfluid Device for the Manufacturing of Chitosan/TPP Nanoparticles: Systematic Optimization and Preliminary Biological Evaluation 20
Combining Reinforcement Learning and PK-PD models to personalize multiple drug administration: an application to Axitinib-Anti-Hypertensive treatment in metastatic renal cancer patients 19
Modeling tumor growth inhibition in Glioblastoma spheroids after exposure to RC-106, a novel sigma receptors modulator 19
A Two-Stages Global Sensitivity Analysis in presence of correlated inputs: Application on a Tumor-in-host-growth Inhibition model based on the Dynamic Energy Budget theory 19
Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approach 19
PopPK-PD modelling of Carboplatin-induced myelosuppression to support therapeutic drug monitoring and dose individualization in cancer patients using Electronic Health Record Data 14
Dealing with stochasticity in precision dosing decision-making processes by fully exploiting PK-PD modelling in Reinforcement Learning algorithms. A practical case-study on Vancomycin continuous infusion in ICU patients 11
Translational modeling of tumor response to treatment: bridging preclinical to clinical studies 11
A Two-Stages Global Sensitivity Analysis by using the delta sensitivity index in presence of correlated inputs: Application on a Tumor Growth Inhibition model based on the Dynamic Energy Budget theory 9
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients 8
A clinical trial simulator to predict the effect of an adaptive dosing regimen of an investigated compound on platelets, white blood cells and haematocrit in patients with Polycythemia Vera 8
mvLognCorrEst: an R package for sampling from multivariate lognormal distributions and estimating correlations from uncomplete correlation matrix 7
Go beyond the limits of genetic algorithm in daily covariate selection practice 7
Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma 7
Model-informed reinforcement learning for enabling precision dosing via adaptive dosing 7
Impact of sampling procedure on individual pharmacokinetic parameter estimation methods 5
Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients 4
Predicting ADMET properties from molecule SMILE: a bottom-up approach using attention-based Graph Neural Networks 4
Predicting Tumor Volume Doubling Time and Progression-Free Survival in Untreated Patients from Patient-Derived-Xenograft (PDX) Models: A Translational Model-Based Approach 4
Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment 3
Totale 1.376
Categoria #
all - tutte 7.506
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.506


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202043 0 0 0 0 2 4 5 11 2 11 7 1
2020/202129 1 1 0 0 2 2 3 9 4 5 1 1
2021/2022151 2 2 10 0 4 4 7 27 10 5 18 62
2022/2023440 48 41 6 27 25 36 2 30 199 1 9 16
2023/2024303 27 62 15 14 25 54 18 20 6 16 8 38
2024/2025227 18 97 35 35 42 0 0 0 0 0 0 0
Totale 1.376